| Year |
Citation |
Score |
| 2020 |
Szőke É, Bálint M, Hetényi C, Markovics A, Elekes K, Pozsgai G, Szűts T, Kéri G, Őrfi L, Sándor Z, Szolcsányi J, Pintér E, Helyes Z. Small molecule somatostatin receptor subtype 4 (sst) agonists are novel anti-inflammatory and analgesic drug candidates. Neuropharmacology. 178: 108198. PMID 32739276 DOI: 10.1016/J.Neuropharm.2020.108198 |
0.362 |
|
| 2019 |
Zsákai L, Sipos A, Dobos J, Erős D, Szántai-Kis C, Bánhegyi P, Pató J, Őrfi L, Matula Z, Mikala G, Kéri G, Peták I, Vályi-Nagy I. Targeted drug combination therapy design based on driver genes. Oncotarget. 10: 5255-5266. PMID 31523388 DOI: 10.18632/Oncotarget.26985 |
0.747 |
|
| 2019 |
Artarini A, Meyer M, Shin YJ, Huber K, Hilz N, Bracher F, Eros D, Orfi L, Keri G, Goedert S, Neuenschwander M, von Kries J, Domovich-Eisenberg Y, Dekel N, Szabadkai I, et al. Regulation of influenza a virus mRNA splicing by CLK1. Antiviral Research. PMID 31176694 DOI: 10.1016/J.Antiviral.2019.06.003 |
0.737 |
|
| 2017 |
Brauswetter D, Gurbi B, Varga A, Várkondi E, Schwab R, Bánhegyi G, Fábián O, Kéri G, Vályi-Nagy I, Peták I. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. Plos One. 12: e0185687. PMID 28957417 DOI: 10.1371/Journal.Pone.0185687 |
0.4 |
|
| 2017 |
Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, et al. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports. 20: 2833-2845. PMID 28930680 DOI: 10.1016/J.Celrep.2017.08.082 |
0.427 |
|
| 2017 |
Ekins S, Godbole AA, Kéri G, Orfi L, Pato J, Bhat RS, Verma R, Bradley EK, Nagaraja V. Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I. Tuberculosis (Edinburgh, Scotland). 103: 52-60. PMID 28237034 DOI: 10.1016/J.Tube.2017.01.005 |
0.414 |
|
| 2016 |
Singh V, Donini S, Pacitto A, Sala C, Hartkoorn RC, Dhar N, Keri G, Ascher DB, Mondésert G, Vocat A, Lupien A, Sommer R, Vermet H, Lagrange S, Buechler J, et al. The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis. Acs Infectious Diseases. PMID 27726334 DOI: 10.1021/Acsinfecdis.6B00102 |
0.378 |
|
| 2016 |
Murányi J, Gyulavári P, Varga A, Bökönyi G, Tanai H, Vántus T, Pap D, Ludányi K, Mező G, Kéri G. Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells. Journal of Peptide Science : An Official Publication of the European Peptide Society. 22: 552-60. PMID 27443981 DOI: 10.1002/Psc.2904 |
0.337 |
|
| 2016 |
Booij TH, Klop MJ, Yan K, Szántai-Kis C, Szokol B, Orfi L, van de Water B, Keri G, Price LS. Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases. Journal of Biomolecular Screening. PMID 27412535 DOI: 10.1177/1087057116657269 |
0.409 |
|
| 2016 |
Garamvölgyi R, Dobos J, Sipos A, Boros S, Illyés E, Baska F, Kékesi L, Szabadkai I, Szántai-Kis C, Kéri G, Őrfi L. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells. European Journal of Medicinal Chemistry. 108: 623-43. PMID 26724730 DOI: 10.1016/J.Ejmech.2015.12.001 |
0.352 |
|
| 2016 |
Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G. Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes. Bioorganic & Medicinal Chemistry Letters. 26: 424-8. PMID 26704265 DOI: 10.1016/J.Bmcl.2015.11.099 |
0.368 |
|
| 2016 |
Yeung AW, Lim YJ, Hastad M, Dang L, Örfi L, Szabadkai I, Kéri G, Terentis AC, King NJ, Witting PK, Thomas SR. Redox Control of the Critical Immune Regulatory Enzyme Indoleamine 2,3-Dioxygenase by NADPH Oxidase 2-Derived Reactive Oxygen Species in Human Monocytes Free Radical Biology and Medicine. 100. DOI: 10.1016/J.Freeradbiomed.2016.10.162 |
0.316 |
|
| 2015 |
Varga A, Gyulavári P, Greff Z, Futosi K, Németh T, Simon-Szabó L, Kerekes K, Szántai-Kis C, Brauswetter D, Kokas M, Borbély G, Erdei A, Mócsai A, Kéri G, Vántus T. Correction: Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro. Plos One. 10: e0144792. PMID 26672602 DOI: 10.1371/Journal.Pone.0144792 |
0.811 |
|
| 2015 |
Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horvath Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, et al. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell. 28: 170-82. PMID 26267534 DOI: 10.1016/J.Ccell.2015.07.001 |
0.351 |
|
| 2015 |
Varga A, Gyulavári P, Greff Z, Futosi K, Németh T, Simon-Szabó L, Kerekes K, Szántai-Kis C, Brauswetter D, Kokas M, Borbély G, Erdei A, Mócsai A, Kéri G, Vántus T. Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro. Plos One. 10: e0124234. PMID 25874616 DOI: 10.1371/journal.pone.0124234 |
0.804 |
|
| 2015 |
Lavoz C, Alique M, Rodrigues-Diez R, Pato J, Keri G, Mezzano S, Egido J, Ruiz-Ortega M. Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway. The Journal of Pathology. 236: 407-20. PMID 25810250 DOI: 10.1002/Path.4537 |
0.303 |
|
| 2015 |
Sipos A, Pató J, Székely R, Hartkoorn RC, Kékesi L, ?rfi L, Szántai-Kis C, Mikušová K, Svetlíková Z, Korduláková J, Nagaraja V, Godbole AA, Bush N, Collin F, Maxwell A, et al. Lead selection and characterization of antitubercular compounds using the Nested Chemical Library. Tuberculosis (Edinburgh, Scotland). 95: S200-6. PMID 25801335 DOI: 10.1016/J.Tube.2015.02.028 |
0.408 |
|
| 2014 |
Pénzes K, Baumann C, Szabadkai I, Orfi L, Kéri G, Ullrich A, Torka R. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Cancer Biology & Therapy. 15: 1571-82. PMID 25482942 DOI: 10.4161/15384047.2014.956634 |
0.302 |
|
| 2014 |
Kékesi L, Sipos A, Németh G, Dancsó A, Illyés E, Boros S, Breza N, Nemes Z, Hegymegi-Barakonyi B, Pató J, Greff Z, Kéri G, Őrfi L. [Pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction]. Acta Pharmaceutica Hungarica. 84: 91-104. PMID 25470976 |
0.352 |
|
| 2014 |
Rybniker J, Chen JM, Sala C, Hartkoorn RC, Vocat A, Benjak A, Boy-Röttger S, Zhang M, Székely R, Greff Z, Orfi L, Szabadkai I, Pató J, Kéri G, Cole ST. Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host & Microbe. 16: 538-48. PMID 25299337 DOI: 10.1016/J.Chom.2014.09.008 |
0.422 |
|
| 2014 |
Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G. Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. Acs Medicinal Chemistry Letters. 5: 298-303. PMID 24900830 DOI: 10.1021/Ml4003309 |
0.398 |
|
| 2014 |
Torka R, Pénzes K, Gusenbauer S, Baumann C, Szabadkai I, Őrfi L, Kéri G, Ullrich A. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Neoplasia (New York, N.Y.). 16: 301-18. PMID 24862757 DOI: 10.1016/J.Neo.2014.03.009 |
0.438 |
|
| 2014 |
Németh G, Greff Z, Sipos A, Varga Z, Székely R, Sebestyén M, Jászay Z, Béni S, Nemes Z, Pirat JL, Volle JN, Virieux D, Gyuris Á, Kelemenics K, Ay E, et al. Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors. Journal of Medicinal Chemistry. 57: 3939-65. PMID 24742150 DOI: 10.1021/Jm401742R |
0.498 |
|
| 2014 |
Baska F, Szabadkai I, Sipos A, Breza N, Szántai-Kis C, Kékesi L, Garamvölgyi R, Nemes Z, Neumann L, Torka R, Ullrich A, Kéri G, Orfi L. Pharmacophore and binding analysis of known and novel b-raf kinase inhibitors Current Medicinal Chemistry. 21: 1938-1955. PMID 24606495 DOI: 10.2174/0929867321666140304152606 |
0.416 |
|
| 2014 |
Schnaiter S, Fürst B, Neu J, Wáczek F, Orfi L, Kéri G, Huber LA, Wunderlich W. Screening for MAPK modulators using an in-cell western assay. Methods in Molecular Biology (Clifton, N.J.). 1120: 121-9. PMID 24470022 DOI: 10.1007/978-1-62703-791-4_8 |
0.361 |
|
| 2013 |
Szokol B, Gyulavári P, Baska F, Ibolya K, Greff Z, Szántai KC, Zoltán O, Peták I, Axel U, Vantus T, Kéri G, Orfi L. [Development and biochemical characterization of EGFR/c-Met dual inhibitors]. Acta Pharmaceutica Hungarica. 83: 121-33. PMID 24575658 |
0.327 |
|
| 2013 |
Haas DA, Bala K, Büsche G, Weidner-Glunde M, Santag S, Kati S, Gramolelli S, Damas M, Dittrich-Breiholz O, Kracht M, Rückert J, Varga Z, Keri G, Schulz TF. The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells. Plos Pathogens. 9: e1003737. PMID 24244164 DOI: 10.1371/Journal.Ppat.1003737 |
0.323 |
|
| 2013 |
Kékesi L, Sipos A, Németh G, Pató J, Breza N, Baska F, Őrfi L, Kéri G. Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines. Bioorganic & Medicinal Chemistry Letters. 23: 6152-5. PMID 24095095 DOI: 10.1016/J.Bmcl.2013.09.005 |
0.419 |
|
| 2013 |
Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, Ramos AM, Eguchi S, Batlle D, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. The Journal of Pathology. 231: 480-94. PMID 24037740 DOI: 10.1002/Path.4250 |
0.365 |
|
| 2013 |
Rayego-Mateos S, Rodrigues-Díez R, Morgado-Pascual JL, Rodrigues Díez RR, Mas S, Lavoz C, Alique M, Pato J, Keri G, Ortiz A, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. Journal of Molecular Cell Biology. 5: 323-35. PMID 23929714 DOI: 10.1093/Jmcb/Mjt030 |
0.342 |
|
| 2013 |
Keri G, Orfi L, Greff Z, Pato J, Szokol B, Kekesi L, Sipos A, Garamvolgyi R. Signal transduction therapy of cancer with kinase inhibitors Current Opinion in Biotechnology. 24. DOI: 10.1016/J.Copbio.2013.05.019 |
0.36 |
|
| 2012 |
Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J, Váradi A, Sarkadi B. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochemical Pharmacology. 84: 260-7. PMID 22548830 DOI: 10.1016/J.Bcp.2012.04.010 |
0.385 |
|
| 2012 |
Borbély G, Huszár M, Varga A, Futosi K, Mócsai A, Orfi L, Idei M, Mandl J, Kéri G, Vántus T. Optimization of important early ADME(T) parameters of NADPH oxidase-4 inhibitor molecules. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 8: 174-81. PMID 22385185 DOI: 10.2174/157340612800493674 |
0.786 |
|
| 2012 |
Fitos I, Simon Á, Zsila F, Mády G, Bencsura Á, Varga Z, orfi L, Kéri G, Visy J. Characterization of binding mode of imatinib to human α1-acid glycoprotein. International Journal of Biological Macromolecules. 50: 788-795. PMID 22142793 DOI: 10.1016/J.Ijbiomac.2011.11.023 |
0.355 |
|
| 2012 |
Dolman ME, van Dorenmalen KM, Pieters EH, Sparidans RW, Lacombe M, Szokol B, Orfi L, Kéri G, Bovenschen N, Storm G, Hennink WE, Kok RJ. Dendrimer-based macromolecular conjugate for the kidney-directed delivery of a multitargeted sunitinib analogue. Macromolecular Bioscience. 12: 93-103. PMID 21998092 DOI: 10.1002/Mabi.201100277 |
0.311 |
|
| 2011 |
Chatterjee J, Laufer B, Beck JG, Helyes Z, Pintér E, Szolcsányi J, Horvath A, Mandl J, Reubi JC, Kéri G, Kessler H. N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation. Acs Medicinal Chemistry Letters. 2: 509-14. PMID 24900340 DOI: 10.1021/Ml200032V |
0.304 |
|
| 2011 |
Harmsen S, Dolman ME, Nemes Z, Lacombe M, Szokol B, Pató J, Kéri G, Orfi L, Storm G, Hennink WE, Kok RJ. Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. Bioconjugate Chemistry. 22: 540-5. PMID 21443263 DOI: 10.1021/bc1005637 |
0.351 |
|
| 2011 |
Németh G, Varga Z, Greff Z, Bencze G, Sipos A, Szántai-Kis C, Baska F, Gyuris A, Kelemenics K, Szathmáry Z, Minárovits J, Kéri G, Orfi L. Novel, selective CDK9 inhibitors for the treatment of HIV infection Current Medicinal Chemistry. 18: 342-358. PMID 21143121 DOI: 10.2174/092986711794839188 |
0.443 |
|
| 2010 |
Magnet S, Hartkoorn RC, Székely R, Pató J, Triccas JA, Schneider P, Szántai-Kis C, Orfi L, Chambon M, Banfi D, Bueno M, Turcatti G, Kéri G, Cole ST. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinburgh, Scotland). 90: 354-60. PMID 20934382 DOI: 10.1016/J.Tube.2010.09.001 |
0.45 |
|
| 2010 |
Breitkopf SB, Oppermann FS, Keri G, Grammel M, Daub H. Proteomics analysis of cellular imatinib targets and their candidate downstream effectors. Journal of Proteome Research. 9: 6033-43. PMID 20866107 DOI: 10.1021/pr1008527 |
0.347 |
|
| 2010 |
Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, et al. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Current Cancer Drug Targets. 10: 332-42. PMID 20370683 DOI: 10.2174/156800910791190184 |
0.384 |
|
| 2010 |
Sharma K, Kumar C, Kéri G, Breitkopf SB, Oppermann FS, Daub H. Quantitative analysis of kinase-proximal signaling in lipopolysaccharide-induced innate immune response. Journal of Proteome Research. 9: 2539-49. PMID 20222745 DOI: 10.1021/Pr901192P |
0.35 |
|
| 2010 |
Schreiber TB, Mäusbacher N, Kéri G, Cox J, Daub H. An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Molecular & Cellular Proteomics : McP. 9: 1047-62. PMID 20071362 DOI: 10.1074/Mcp.M900486-Mcp200 |
0.354 |
|
| 2010 |
Huszár M, Varga A, Horváth A, Loránd T, Agócs A, Idei M, Mandl J, Vántus T, Kéri G. Comparative characterization of experimental and calculated lipophilicity and anti-tumour activity of isochromanone derivatives. Current Medicinal Chemistry. 17: 321-33. PMID 20015044 DOI: 10.2174/092986710790192703 |
0.325 |
|
| 2009 |
Hegedűs C, Özvegy‐Laczka C, Apáti Á, Magócsi M, Német K, Őrfi L, Kéri G, Katona M, Takáts Z, Váradi A, Szakács G, Sarkadi B. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties British Journal of Pharmacology. 158: 1153-1164. PMID 19785662 DOI: 10.1111/J.1476-5381.2009.00383.X |
0.422 |
|
| 2009 |
Sharma K, Weber C, Bairlein M, Greff Z, Kéri G, Cox J, Olsen JV, Daub H. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nature Methods. 6: 741-4. PMID 19749761 DOI: 10.1038/Nmeth.1373 |
0.359 |
|
| 2009 |
Reinl T, Nimtz M, Hundertmark C, Johl T, Kéri G, Wehland J, Daub H, Jänsch L. Quantitative phosphokinome analysis of the Met pathway activated by the invasin internalin B from Listeria monocytogenes. Molecular & Cellular Proteomics : McP. 8: 2778-95. PMID 19640851 DOI: 10.1074/Mcp.M800521-Mcp200 |
0.409 |
|
| 2009 |
Zsila F, Fitos I, Bencze G, Kéri G, Orfi L. Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Current Medicinal Chemistry. 16: 1964-77. PMID 19519376 DOI: 10.2174/092986709788682191 |
0.404 |
|
| 2009 |
Herczenik E, Varga Z, Eros D, Makó V, Oroszlán M, Rugonfalvi-Kiss S, Romics L, Füst G, Kéri G, Orfi L, Cervenak L. Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. Journal of Receptor and Signal Transduction Research. 29: 75-83. PMID 19519173 DOI: 10.1080/10799890902857976 |
0.799 |
|
| 2009 |
Hegymegi-Barakonyi B, Eros D, Szántai-Kis C, Breza N, Bánhegyi P, Szabó GV, Várkondi E, Peták I, Orfi L, Kéri G. Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. Current Opinion in Molecular Therapeutics. 11: 308-21. PMID 19479664 |
0.777 |
|
| 2009 |
Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Kéri G, Mann M, Daub H. Large-scale proteomics analysis of the human kinome. Molecular & Cellular Proteomics : McP. 8: 1751-64. PMID 19369195 DOI: 10.1074/Mcp.M800588-Mcp200 |
0.422 |
|
| 2009 |
Eros D, Orfi L, Csuka I, Kéri G, Hrabák A. Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Amino Acids. 36: 483-92. PMID 18504524 DOI: 10.1007/S00726-008-0106-X |
0.728 |
|
| 2008 |
Miyazaki A, Tsuda Y, Fukushima S, Yokoi T, Vántus T, Bökönyi G, Szabó E, Horváth A, Kéri G, Okada Y. New cyclic somatostatin analogues containing a pyrazinone ring: importance of Tyr for antiproliferative activity. Bioorganic & Medicinal Chemistry Letters. 18: 6199-201. PMID 18930401 DOI: 10.1016/J.Bmcl.2008.10.001 |
0.379 |
|
| 2008 |
Bánhegyi P, Wáczek F, Székelyhidi Z, Hegymegi-Barakonyi B, Kéri G, Orfi L. [Novel method for the synthesis of carboxamides from low reactivity esters: synthesis of 2-acylamino-1-benzothiophene-3-carboxamides]. Acta Pharmaceutica Hungarica. 78: 75-8. PMID 18807387 |
0.757 |
|
| 2008 |
Breza N, Pato J, Orfi L, Hegymegi-Barakonyi B, Banhegyi P, Varkondi E, Borbely G, Petak I, Keri G. Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases. Journal of Receptor and Signal Transduction Research. 28: 361-73. PMID 18702009 DOI: 10.1080/10799890802242618 |
0.814 |
|
| 2008 |
Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Körner R, Greff Z, Kéri G, Stemmann O, Mann M. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Molecular Cell. 31: 438-48. PMID 18691976 DOI: 10.1016/J.Molcel.2008.07.007 |
0.39 |
|
| 2008 |
Miyazaki A, Tsuda Y, Fukushima S, Yokoi T, Vántus T, Bökönyi G, Szabó E, Horváth A, Kéri G, Okada Y. Synthesis of somatostatin analogues containing C-terminal adamantane and their antiproliferative properties. Journal of Medicinal Chemistry. 51: 5121-4. PMID 18680358 DOI: 10.1021/Jm701599W |
0.347 |
|
| 2008 |
Varkondi E, Pinter F, Robert K, Schwab R, Breza N, Orfi L, Keri G, Petak I. Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor. Journal of Receptor and Signal Transduction Research. 28: 295-306. PMID 18569529 DOI: 10.1080/10799890802084671 |
0.417 |
|
| 2008 |
Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. The Journal of Molecular Diagnostics : Jmd. 10: 160-8. PMID 18258923 DOI: 10.2353/Jmoldx.2008.070125 |
0.31 |
|
| 2008 |
Székely R, Wáczek F, Szabadkai I, Németh G, Hegymegi-Barakonyi B, Eros D, Szokol B, Pató J, Hafenbradl D, Satchell J, Saint-Joanis B, Cole ST, Orfi L, Klebl BM, Kéri G. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Immunology Letters. 116: 225-31. PMID 18258308 DOI: 10.1016/J.Imlet.2007.12.005 |
0.803 |
|
| 2007 |
Schwab R, Micsik T, Szokolóczi O, Schafer E, Tihanyi B, Tihanyi T, Kupcsulik P, Diófalvi K, Mersich T, Besznyak I, Zarand A, Mihalik R, Sarkadi B, Kéri G, Pap A, et al. Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors. Assay and Drug Development Technologies. 5: 541-50. PMID 17767422 DOI: 10.1089/Adt.2007.067 |
0.305 |
|
| 2007 |
Hallgas B, Dobos Z, Agócs A, Idei M, Kéri G, Loránd T, Mészáros G. Lipophilicity and antiproliferative activity profiling of 2-benzylidencycloalkanones. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 856: 148-55. PMID 17644496 DOI: 10.1016/J.Jchromb.2007.05.027 |
0.434 |
|
| 2007 |
Gonzalo T, Beljaars L, van de Bovenkamp M, Temming K, van Loenen AM, Reker-Smit C, Meijer DK, Lacombe M, Opdam F, Kéri G, Orfi L, Poelstra K, Kok RJ. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. The Journal of Pharmacology and Experimental Therapeutics. 321: 856-65. PMID 17369283 DOI: 10.1124/Jpet.106.114496 |
0.351 |
|
| 2007 |
Steták A, Veress R, Ovádi J, Csermely P, Kéri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Research. 67: 1602-8. PMID 17308100 DOI: 10.1158/0008-5472.Can-06-2870 |
0.337 |
|
| 2007 |
Wissing J, Jänsch L, Nimtz M, Dieterich G, Hornberger R, Kéri G, Wehland J, Daub H. Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Molecular & Cellular Proteomics : McP. 6: 537-47. PMID 17192257 DOI: 10.1074/Mcp.T600062-Mcp200 |
0.4 |
|
| 2006 |
Temming K, Lacombe M, Moorlag H, Asgeirsdottir SA, Orfi L, Keri G, Poelstra K, Molema G, Kok RJ. Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules. Journal of Controlled Release. 116. PMID 17718970 DOI: 10.1016/J.Jconrel.2006.09.048 |
0.38 |
|
| 2006 |
Hrabák A, Bökönyi G, Orfi L, Bajor T, Kéri G. Comparison of the cytotoxic effects of receptor tyrosine kinase inhibitors on macrophage functions; possible side effects in the immune defense. Immunology Letters. 107: 169-75. PMID 17098294 DOI: 10.1016/J.Imlet.2006.09.006 |
0.432 |
|
| 2006 |
Temming K, Lacombe M, Schaapveld RQ, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium. Chemmedchem. 1: 1200-3. PMID 16991175 DOI: 10.1002/Cmdc.200600201 |
0.369 |
|
| 2006 |
Temming K, Lacombe M, van der Hoeven P, Prakash J, Gonzalo T, Dijkers EC, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. Bioconjugate Chemistry. 17: 1246-55. PMID 16984135 DOI: 10.1021/Bc0600158 |
0.398 |
|
| 2006 |
Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQ, de Borst MH, van Goor H, Henning RH, Proost JH, Moolenaar F, Këri G, Meijer DK, Poelstra K, Kok RJ. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. The Journal of Pharmacology and Experimental Therapeutics. 319: 8-19. PMID 16807361 DOI: 10.1124/Jpet.106.106054 |
0.321 |
|
| 2006 |
Szántai-Kis C, Kövesdi I, Eros D, Bánhegyi P, Ullrich A, Kéri G, Orfi L. Prediction oriented QSAR modelling of EGFR inhibition. Current Medicinal Chemistry. 13: 277-87. PMID 16475937 DOI: 10.2174/092986706775476098 |
0.767 |
|
| 2006 |
Keri G, Orfi L, Eros D, Hegymegi-Barakonyi B, Szantai-Kis C, Horvath Z, Waczek F, Marosfalvi J, Szabadkai I, Pato J, Greff Z, Hafenbradl D, Daub H, Muller G, Klebl B, et al. Signal transduction therapy with rationally designed kinase inhibitors Current Signal Transduction Therapy. 1: 67-95. DOI: 10.2174/157436206775269190 |
0.755 |
|
| 2005 |
Székelyhidi Z, Pató J, Hegymegi-Barakonyi B, Bánhegyi P, Mészáros G, Kéri G, Orfi L. [Synthesis of thiophene and alpha-terthiophene derivatives with antiproliferative activity]. Acta Pharmaceutica Hungarica. 75: 185-93. PMID 16711395 |
0.779 |
|
| 2005 |
Varkondi E, Schäfer E, Bökönyi G, Gyökeres T, Orfi L, Petak I, Pap A, Szokoloczi O, Keri G, Schwab R. Comparison of ELISA-based tyrosine kinase assays for screening EGFR inhibitors. Journal of Receptor and Signal Transduction Research. 25: 45-56. PMID 15960394 DOI: 10.1081/Rrs-200055095 |
0.442 |
|
| 2005 |
Székelyhidi Z, Pató J, Wáczek F, Bánhegyi P, Hegymegi-Barakonyi B, Erös D, Mészáros G, Hollósy F, Hafenbradl D, Obert S, Klebl B, Kéri G, Orfi L. Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Bioorganic & Medicinal Chemistry Letters. 15: 3241-6. PMID 15925511 DOI: 10.1016/J.Bmcl.2005.04.064 |
0.761 |
|
| 2005 |
Hallgas B, Dobos Z, Osz E, Hollósy F, Schwab RE, Szabó EZ, Eros D, Idei M, Kéri G, Lóránd T. Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 819: 283-91. PMID 15833292 DOI: 10.1016/J.Jchromb.2005.02.014 |
0.759 |
|
| 2005 |
Sukopp M, Schwab R, Marinelli L, Biron E, Heller M, Várkondi E, Pap A, Novellino E, Kéri G, Kessler H. Structure-activity relationship studies optimizing the antiproliferative activity of novel cyclic somatostatin analogues containing a restrained cyclic beta-amino acid. Journal of Medicinal Chemistry. 48: 2916-26. PMID 15828830 DOI: 10.1021/Jm049500J |
0.319 |
|
| 2005 |
Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A, Buday L, Kéri G, Német K, Sarkadi B. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Research. 65: 1770-7. PMID 15753373 DOI: 10.1158/0008-5472.Can-04-3303 |
0.401 |
|
| 2005 |
Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, Wissing J, Daub H. Cellular targets of gefitinib. Cancer Research. 65: 379-82. PMID 15695376 |
0.327 |
|
| 2005 |
Szakács Z, Béni S, Varga Z, Orfi L, Kéri G, Noszál B. Acid-base profiling of imatinib (gleevec) and its fragments. Journal of Medicinal Chemistry. 48: 249-55. PMID 15634018 DOI: 10.1021/Jm049546C |
0.326 |
|
| 2005 |
Buschbeck M, Hofbauer S, Di Croce L, Keri G, Ullrich A. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. Embo Reports. 6: 63-9. PMID 15608616 DOI: 10.1038/Sj.Embor.7400316 |
0.4 |
|
| 2005 |
Kéri G, Schwab R, Szokolóczi O, Szüts T, Szolcsányi J. TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development International Journal of Peptide Research and Therapeutics. 11: 3-15. DOI: 10.1007/S10989-004-1715-1 |
0.325 |
|
| 2004 |
Orfi L, Wáczek F, Pató J, Varga I, Hegymegi-Barakonyi B, Houghten RA, Kéri G. Improved, high yield synthesis of 3H-quinazolin-4-ones, the key intermediates of recently developed drugs. Current Medicinal Chemistry. 11: 2549-53. PMID 15544462 DOI: 10.2174/0929867043364423 |
0.452 |
|
| 2004 |
Ozvegy-Laczka C, Hegedus T, Várady G, Ujhelly O, Schuetz JD, Váradi A, Kéri G, Orfi L, Német K, Sarkadi B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Molecular Pharmacology. 65: 1485-95. PMID 15155841 DOI: 10.1124/Mol.65.6.1485 |
0.375 |
|
| 2004 |
Vántus T, Vertommen D, Saelens X, Rykx A, De Kimpe L, Vancauwenbergh S, Mikhalap S, Waelkens E, Kéri G, Seufferlein T, Vandenabeele P, Rider MH, Vandenheede JR, Van Lint J. Doxorubicin-induced activation of protein kinase D1 through caspase-mediated proteolytic cleavage: identification of two cleavage sites by microsequencing. Cellular Signalling. 16: 703-9. PMID 15093611 DOI: 10.1016/J.Cellsig.2003.11.009 |
0.321 |
|
| 2004 |
Kéri G, Racz G, Magyar K, Orfi L, Horváth A, Schwab R, Hegymegi BB, Szende B. Pro-apoptotic and anti-apoptotic molecules affecting pathways of signal transduction. Annals of the New York Academy of Sciences. 1010: 109-12. PMID 15033704 DOI: 10.1196/Annals.1299.018 |
0.434 |
|
| 2004 |
Hollósy F, Kéri G. Plant-derived protein tyrosine kinase inhibitors as anticancer agents. Current Medicinal Chemistry. Anti-Cancer Agents. 4: 173-97. PMID 15032721 DOI: 10.2174/1568011043482124 |
0.462 |
|
| 2004 |
Erös D, Kéri G, Kövesdi I, Szántai-Kis C, Mészáros G, Orfi L. Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods. Mini Reviews in Medicinal Chemistry. 4: 167-77. PMID 14965289 DOI: 10.2174/1389557043487466 |
0.748 |
|
| 2004 |
Hallgas B, Patonay T, Kiss-Szikszai A, Dobos Z, Hollósy F, Eros D, Orfi L, Kéri G, Idei M. Comparison of measured and calculated lipophilicity of substituted aurones and related compounds. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 801: 229-35. PMID 14751791 DOI: 10.1016/J.Jchromb.2003.11.021 |
0.75 |
|
| 2004 |
Dobos Z, Lóránd T, Hollósy F, Hallgas B, Eros D, Mészáros G, Kéri G, Idei M. Determination of the basicity of Mannich ketones by capillary electrophoresis. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 799: 179-83. PMID 14659451 DOI: 10.1016/J.Jchromb.2003.10.038 |
0.756 |
|
| 2004 |
Miyazaki A, Yokoi T, Tachibana Y, Enomoto R, Lee E, Bokonyi G, Keri G, Tsuda Y, Okada Y. Design and synthesis of novel type somatostatin analogs with antiproliferative activities on A431 tumor cells Tetrahedron Letters. 45: 6323-6327. DOI: 10.1016/J.Tetlet.2004.06.105 |
0.326 |
|
| 2003 |
Tejeda M, Gaál D, Csuka O, Ullrich A, Schwab R, Pap A, Horváth A, Kéri G. The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen. Cancer Detection and Prevention. 27: 155-62. PMID 12670528 DOI: 10.1016/S0361-090X(03)00022-9 |
0.306 |
|
| 2002 |
Hollósy F, Seprödi J, Orfi L, Erös D, Kéri G, Idei M. Evaluation of lipophilicity and antitumour activity of parallel carboxamide libraries. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 780: 355-63. PMID 12401362 DOI: 10.1016/S1570-0232(02)00545-7 |
0.768 |
|
| 2002 |
Pintér E, Helyes Z, Németh J, Pórszász R, Pethö G, Thán M, Kéri G, Horváth A, Jakab B, Szolcsányi J. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn-Schmiedeberg's Archives of Pharmacology. 366: 142-50. PMID 12122501 DOI: 10.1007/S00210-002-0563-9 |
0.301 |
|
| 2002 |
Hegedus T, Orfi L, Seprodi A, Váradi A, Sarkadi B, Kéri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochimica Et Biophysica Acta. 1587: 318-25. PMID 12084474 DOI: 10.1016/S0925-4439(02)00095-9 |
0.372 |
|
| 2002 |
Hollósy F, Lóránd T, Orfi L, Erös D, Kéri G, Idei M. Relationship between lipophilicity and antitumor activity of molecule library of Mannich ketones determined by high-performance liquid chromatography, clogP calculation and cytotoxicity test. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 768: 361-8. PMID 11888064 DOI: 10.1016/S1570-0232(02)00004-1 |
0.773 |
|
| 2002 |
Hollósy F, Lóránd T, Őrfi L, Erős D, Kéri G, Idei M. EVALUATION OF HYDROPHOBICITY AND ANTITUMOR ACTIVITY OF A MOLECULE LIBRARY OF MANNICH KETONES OF CYCLOALKANONES Journal of Liquid Chromatography & Related Technologies. 25: 1129-1143. DOI: 10.1081/Jlc-120003430 |
0.393 |
|
| 2001 |
Gruner SAW, Kéri G, Schwab R, Venetianer aA, Kessler H. Sugar amino acid containing somatostatin analogues that induce apoptosis in both drug-sensitive and multidrug-resistant tumor cells. Organic Letters. 3: 3723-3725. PMID 11700122 DOI: 10.1021/Ol0166698 |
0.314 |
|
| 2001 |
Vántus T, Kéri G, Krivickiene Z, Valius M, Steták A, Keppens S, Csermely P, Bauer PI, Bökönyi G, Declercq W, Vandenabeele P, Merlevede W, Vandenheede JR. The somatostatin analogue TT-232 induces apoptosis in A431 cells: sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinases. Cellular Signalling. 13: 717-25. PMID 11602182 DOI: 10.1016/S0898-6568(01)00194-2 |
0.397 |
|
| 2001 |
Koncz G, Tóth GK, Bökönyi G, Kéri G, Pecht I, Medgyesi D, Gergely J, Sármay G. Co-clustering of Fcgamma and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein. European Journal of Biochemistry. 268: 3898-906. PMID 11453982 DOI: 10.1046/J.1432-1327.2001.02295.X |
0.395 |
|
| 2001 |
Steták A, Lankenau A, Vántus T, Csermely P, Ullrich A, Kéri G. The Antitumor Somatostatin Analogue TT-232 Induces Cell Cycle Arrest through PKCδ and c-Src Biochemical and Biophysical Research Communications. 285: 483-488. PMID 11444868 DOI: 10.1006/Bbrc.2001.5199 |
0.362 |
|
| 1999 |
Tóth I, Malkinson JP, Flinn NS, Drouillat B, Horváth A, Erchegyi J, Idei M, Venetianer A, Artursson P, Lazorova L, Szende B, Kéri G. Novel lipoamino acid- and liposaccharide-based system for peptide delivery: application for oral administration of tumor-selective somatostatin analogues. Journal of Medicinal Chemistry. 42: 4010-3. PMID 10508449 DOI: 10.1021/Jm9910167 |
0.334 |
|
| 1999 |
Õrfi L, Wáczek F, Kövesdi I, Mészáros G, Idei M, Horvath A, Hollósy F, Mák M, Szegedi Z, Szende B, Kéri G. New antitumor leads from a peptidomimetic library Letters in Peptide Science. 6: 325-333. DOI: 10.1007/Bf02443428 |
0.46 |
|
| 1996 |
Ôrfi L, Kökösi J, Szász G, Kövesdi I, Mák M, Teplán I, Kéri G. Heterocondensed quinazolones: Synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-1h,6h-[1,4]oxazino-[3,4-b]quinazolin-6-one derivatives Bioorganic & Medicinal Chemistry. 4: 547-551. PMID 8735842 DOI: 10.1016/0968-0896(96)00040-5 |
0.395 |
|
| 1995 |
Balogh A, Csuka O, Teplán I, Kéri G. Phosphatidylcholine could be the source of 1,2-DAG which activates protein kinase C in EGF-stimulated colon carcinoma cells (HT29). Cellular Signalling. 7: 793-801. PMID 8593248 DOI: 10.1016/0898-6568(95)02007-1 |
0.372 |
|
| 1993 |
Balogh Á, Kéri G, Teplán I, Csuka O. Epidermal growth factor increases 32P incorporation into phosphatidylcholine and protein kinase C activity in colon carcinoma cell line (HT29). Cellular Signalling. 5: 795-802. PMID 8130082 DOI: 10.1016/0898-6568(93)90040-S |
0.368 |
|
| 1993 |
Kéri G, Mezö I, Horváth A, Vadász Z, Balogh A, Idei M, Vántus T, Teplán I, Mák M, Horváth J. Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. Biochemical and Biophysical Research Communications. 191: 681-7. PMID 8096383 DOI: 10.1006/bbrc.1993.1271 |
0.32 |
|
| 1991 |
Kéri G, Balogh A, Szöke B, Teplán I, Csuka O. Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line. Tumor Biology. 12: 61-67. DOI: 10.1159/000217689 |
0.357 |
|
| 1988 |
Kéri G, Balogh A, Teplán I, Csuka O. Comparison of the tyrosine kinase activity with the proliferation rate in human colon solid tumors and tumor cell lines. Tumor Biology. 9: 315-322. PMID 3206110 DOI: 10.1159/000217578 |
0.345 |
|
| Show low-probability matches. |